{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP3A4+probe&page=2",
    "query": {
      "intervention": "CYP3A4 probe",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP3A4+probe&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T10:12:51.445Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07486713",
      "title": "Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "AML (Acute Myeloid Leukemia)",
        "Glioma",
        "Cholangiocarcinoma",
        "Solid Tumor Malignancies"
      ],
      "interventions": [
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        },
        {
          "name": "CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2026-02-23",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 2,
      "location_summary": "Orange, California • New York, New York",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07486713"
    },
    {
      "nct_id": "NCT05076877",
      "title": "A Study of Lazertinib (JNJ-73841937) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lazertinib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-17",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05076877"
    },
    {
      "nct_id": "NCT05694533",
      "title": "Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "INDV-2000",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indivior Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-03-16",
      "completion_date": "2023-05-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-28",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05694533"
    },
    {
      "nct_id": "NCT03028103",
      "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Lymphoma",
        "Mantle Cell Lymphoma",
        "Advanced Solid Tumor",
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tazemetostat",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Repaglinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Epizyme, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2017-03-27",
      "completion_date": "2019-11-29",
      "has_results": true,
      "last_update_posted_date": "2023-06-26",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • Tampa, Florida • New York, New York",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03028103"
    },
    {
      "nct_id": "NCT04049786",
      "title": "Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "Bariatric Surgery",
        "Roux-en Y Gastric Bypass"
      ],
      "interventions": [
        {
          "name": "Digestive biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Carvedilol 25mg",
          "type": "DRUG"
        },
        {
          "name": "Serial blood sampling for PK analysis",
          "type": "PROCEDURE"
        },
        {
          "name": "Metoprolol 100 mg for CYP2D6 phenotyping",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin 40mg",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 2 mg for CYP3A4 phenotyping",
          "type": "DRUG"
        },
        {
          "name": "Genotyping",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Natalia Valadares de Moraes",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2019-06-01",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049786"
    },
    {
      "nct_id": "NCT03948243",
      "title": "Licorice Botanical Dietary Supplements - Metabolism and Safety in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Food-drug Interaction"
      ],
      "interventions": [
        {
          "name": "Licorice",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Alprazolam 2 MG",
          "type": "DRUG"
        },
        {
          "name": "Caffeine 100 MG",
          "type": "DRUG"
        },
        {
          "name": "Tolbutamide 250 mg",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 79 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2019-04-01",
      "completion_date": "2022-04-22",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03948243"
    },
    {
      "nct_id": "NCT04958226",
      "title": "A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumour"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 21,
      "start_date": "2021-10-15",
      "completion_date": "2023-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04958226"
    },
    {
      "nct_id": "NCT05631704",
      "title": "A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH4524184",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 84,
      "start_date": "2022-12-02",
      "completion_date": "2023-07-27",
      "has_results": false,
      "last_update_posted_date": "2025-12-29",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05631704"
    },
    {
      "nct_id": "NCT02762123",
      "title": "A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "BMS-986142 200mg",
          "type": "DRUG"
        },
        {
          "name": "BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)",
          "type": "DRUG"
        },
        {
          "name": "BMS-986142 350mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2016-05",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762123"
    },
    {
      "nct_id": "NCT01836198",
      "title": "The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LY2409021",
          "type": "DRUG"
        },
        {
          "name": "Gemfibrozil",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Clarithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2013-05",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-09-26T10:12:51.445Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01836198"
    }
  ]
}